NAS
REGN icon

Nykredit A/S’s Regeneron Pharmaceuticals REGN Stock Holding History

Nykredit A/S’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$26.1M Buy
+41,782
New +$28.4M 0.08% 194

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Nykredit A/S's REGN Position: Q2 2026 in Review

Nykredit A/S opened a new position in Regeneron Pharmaceuticals (REGN) in Q2 2026: 41,782 shares worth $26.1M. The stake represents 0.08% of the portfolio and ranks #194 among its holdings.

1,073 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Nykredit A/S held 41,782 shares of Regeneron Pharmaceuticals worth $26.1M as of Q2 2026.
  • Regeneron Pharmaceuticals was a new Nykredit A/S position in Q2 2026.
  • Regeneron Pharmaceuticals made up 0.08% of Nykredit A/S's portfolio in Q2 2026, its #194 holding.
  • 1,073 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Nykredit A/S's 13F filing for Q2 2026, filed 13 Aug 2026.